A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 28; no. 15_suppl; p. 2599
Main Authors Molife, L. R., Forster, M. D., Krebs, M., Pwint, T., Middleton, M. R., Kaye, S. B., McCormack, P., Swaisland, H., Carmichael, J., Ranson, M.
Format Journal Article
LanguageEnglish
Published 20.05.2010
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2010.28.15_suppl.2599